Cargando…
Systemic Inflammation, Coagulation, and Clinical Risk in the START Trial
BACKGROUND: The Strategic Timing of AntiRetroviral Treatment (START) trial demonstrated that immediate (at CD4+ >500 cells/µL) vs deferred (to CD4+ <350 cells/µL or AIDS) antiretroviral therapy (ART) initiation reduced risk for AIDS and serious non-AIDS (SNA). We investigated associations of i...
Autores principales: | Baker, Jason V, Sharma, Shweta, Grund, Birgit, Rupert, Adam, Metcalf, Julia A, Schechter, Mauro, Munderi, Paula, Aho, Inka, Emery, Sean, Babiker, Abdel, Phillips, Andrew, Lundgren, Jens D, Neaton, James D, Lane, H Clifford |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5751061/ https://www.ncbi.nlm.nih.gov/pubmed/29308409 http://dx.doi.org/10.1093/ofid/ofx262 |
Ejemplares similares
-
LB2305. Long Term Benefits from Early Antiretroviral Therapy Initiation in HIV Infection: Findings from the Extended Follow-up of the START Trial
por: Babiker, Abdel G, et al.
Publicado: (2022) -
Early Antiretroviral Therapy at High CD4 Counts Does Not Improve Arterial Elasticity: A Substudy of the Strategic Timing of AntiRetroviral Treatment (START) Trial
por: Baker, Jason V., et al.
Publicado: (2016) -
When to start antiretroviral therapy: the need for an evidence base during early HIV infection
por: Lundgren, Jens D, et al.
Publicado: (2013) -
Comparison of the Outcomes of Individuals With Medically Attended Influenza A and B Virus Infections Enrolled in 2 International Cohort Studies Over a 6-Year Period: 2009–2015
por: Dwyer, Dominic E, et al.
Publicado: (2017) -
Inflammatory and Coagulation Biomarkers and Mortality in Patients with HIV Infection
por: Kuller, Lewis H, et al.
Publicado: (2008)